We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PNEXF market cap is 184.01B. The company's latest EPS is EUR -0.7729 and P/E is -6469.14.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 2.69M | 255k | 21k | 4.39M | 7.43M |
| Operating Income | -23.74M | -23.58M | -20.76M | -25.77M | -27.52M |
| Net Income | -22.19M | -22.75M | -21.02M | -25.18M | -28.44M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 31.39M | 22.84M | 21.55M | 16.2M | 6.59M |
| Total Liabilities | 59.64M | 31.21M | 34.74M | 35.67M | 40.98M |
| Total Equity | -28.26M | -8.36M | -13.19M | -19.47M | -34.38M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -17.18M | -21.57M | -16.15M | -23.56M | -25.54M |
| Investing | -363k | 175k | -177k | -58k | 434k |
| Financing | 27.85M | 15.08M | 11.15M | 20.51M | 17.53M |
| Market Cap | 184.01B |
| Price to Earnings Ratio | -6469.14 |
| Price to Sales Ratio | 24.76k |
| Price to Cash Ratio | 308.64k |
| Price to Book Ratio | -5.35k |
| Dividend Yield | - |
| Shares Outstanding | 36.8M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Pharnext (CE) |
| Address |
9 rue des filles saint thomas paris, paris 75002 |
| Website | https://www.pharnext.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
